Skip to main content
padlock icon - secure page this page is secure

Clinical outcomes in patients with advanced epidermal growth factor receptor‐mutated non‐small‐cell lung cancer in South Western Sydney Local Health District

Buy Article:

$52.00 + tax (Refund Policy)

Epidermal growth factor receptor (EGFR)‐mutated non‐small‐cell lung cancer (NSCLC) is a subgroup of oncogene addicted lung cancer that predicts response to tyrosine kinase inhibitors (TKI). However, there is variability in response and survival outcomes in patients with EGFR mutation treated with TKI.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: epidermal growth factor receptor; non‐small‐cell lung cancer; prognostic factors; survival; tyrosine kinase inhibitors

Document Type: Research Article

Publication date: December 1, 2017

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more